Get the Stockscreener App
1.51
0.00%
0.00
Pre-market:
1.51
Opko Health Inc stock is traded at $1.51, with a volume of 1.29M.
It is up +0.00% in the last 24 hours and up +7.86% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.51
Open:
$1.53
24h Volume:
1.29M
Relative Volume:
0.54
Market Cap:
$1.20B
Revenue:
$711.41M
Net Income/Loss:
$-133.73M
P/E Ratio:
-7.9474
EPS:
-0.19
Net Cash Flow:
$-199.99M
1W Performance:
-4.43%
1M Performance:
+7.86%
6M Performance:
+6.71%
1Y Performance:
+3.42%
1-Day Range:
$1.49
$1.5387
1-Week Range:
$1.49
$1.595
52-Week Range:
$1.11
$2.035
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.51 | 1.20B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
How OPKO Health Inc. stock performs in weak economyMarket Growth Report & Entry Point Confirmation Alerts - newser.com
When is the best time to exit OPKO Health Inc.Dollar Strength & AI Based Buy and Sell Signals - newser.com
Analyzing OPKO Health Inc. with multi timeframe chartsMarket Growth Summary & Expert Curated Trade Ideas - newser.com
OPKO Health Experiences Evaluation Revision Amid Mixed Market Signals and Performance Trends - Markets Mojo
OPKO Health (NASDAQ:OPK) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Clinical Laboratory Tests Market See Incredible Growth 2025-2032 | ARUP Laboratories, OPKO Health, Inc., UNILABS - industrytoday.co.uk
Smart tools for monitoring OPKO Health Inc.’s price actionJuly 2025 PostEarnings & Safe Entry Zone Tips - newser.com
Real time pattern detection on OPKO Health Inc. stock2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
NextPlat Issues CEO Shareholder Update Letter - Benzinga
OPKO acquiring company from Barcelona - Law.com
Can machine learning forecast OPKO Health Inc. recoveryPortfolio Return Summary & Safe Entry Zone Identification - newser.com
Why OPKO Health Inc. stock attracts global investorsMarket Volume Summary & Reliable Momentum Entry Alerts - newser.com
Technical signs of recovery in OPKO Health Inc.July 2025 Highlights & Fast Moving Market Watchlists - newser.com
How OPKO Health Inc. (XCY) stock reacts to stronger dollarJuly 2025 Catalysts & Weekly Chart Analysis and Guides - newser.com
How to manage a losing position in OPKO Health Inc.Weekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
Ranking OPKO Health Inc. among high performing stocks via toolsQuarterly Earnings Summary & Entry Point Confirmation Alerts - newser.com
What institutional flow reveals about OPKO Health Inc.Portfolio Update Report & Breakout Confirmation Trade Signals - newser.com
OPKO Health (OPK): Valuation Insights as Clinical Pipeline Progress and Asset Sales Draw Investor Focus - Sahm
Washington Growth Strategies LLC Has $1.79 Million Position in OPKO Health, Inc. $OPK - MarketBeat
OPKO Health (OPK) Is Up 7.7% After Advancing Immuno-Oncology Pipeline and CEO Boosts Stake Has the Bull Case Changed? - Sahm
Why OPKO Health (OPK) Is Up 7.7% After Advancing Immuno-Oncology Pipeline and Notable Insider Buying - Sahm
Opko Health (OPK) Reports Fiscal Q2 2025 Results - MSN
What machine learning models say about OPKO Health Inc.July 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
OPKO Health, Inc. (OPK)’s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1 - Yahoo Finance
What analysts say about OPKO Health Inc stockCandlestick Trading Patterns & Minimal Investment Profits - earlytimes.in
Labcorp to buy certain assets of OPKO unit BioReference Health - MSN
12 Healthcare Stocks with Insider Buying in 2025 - Insider Monkey
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands - MSN
Down Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma - Barchart.com
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):